Stay updated on Dupilumab in Bullous Pemphigoid Adults Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page.

Latest updates to the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a new revision entry v3.5.4 and removed the prior entry v3.5.3 from the page's revision history.SummaryDifference0.0%

- Check25 days agoChange DetectedThe Taiwan site entry changed from Taoyuan, Taiwan, 33305 to Taoyuan City, Taiwan, 33305. This clarifies the exact city designation for that study site.SummaryDifference0.0%

- Check39 days agoChange DetectedUpdated the ClinicalTrials.gov page revision/version number from “v3.5.2” to “v3.5.3,” reflecting a site update rather than a change to the study’s details.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision: v3.5.2.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision: v3.5.0 added. Revision: v3.4.3 removed.SummaryDifference0.0%

- Check82 days agoChange DetectedResults posted on 2026-03-06 introduce a comprehensive Results section with primary and secondary efficacy outcomes (OCS exposure, BPDAI scores, pruritus NRS, ABQOL, BP involvement, and autoantibody titers) plus safety data through Week 64. Several previously reported metrics (e.g., sustained remission proportions and some BPDAI-related endpoints) were removed.SummaryDifference6%

Stay in the know with updates to Dupilumab in Bullous Pemphigoid Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Bullous Pemphigoid Adults Clinical Trial page.